Memorial Sloan Kettering

The trials here

What the 40 trials at this site are about, from their registry records.

Conditions

• Childhood cancers9 trials
• Lung cancer7 trials
• Sarcoma5 trials
• Colorectal cancer4 trials
• Head and neck cancer4 trials
• Acute myeloid leukaemia3 trials
• Chronic myeloid leukaemia3 trials
• Melanoma3 trials
• Myelodysplastic syndromes3 trials
• Myeloproliferative neoplasms3 trials
• Ovarian cancer3 trials
• Pancreatic cancer3 trials
• and 15 more

Phase

• Phase 213 trials
• Phase 18 trials
• Phase 1/28 trials
• Phase 34 trials
• Phase 42 trials

Status

• Active, not recruiting18 trials
• Recruiting11 trials
• Completed7 trials
• Terminated2 trials
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Novartis Pharmaceuticals6 trials
• Genentech, Inc.2 trials
• Agenus Inc.1 trial
• ALX Oncology Inc.1 trial
• American Heart Association1 trial
• and 29 more

Running trials

• Recruiting

  A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT07336472· Phase 1/2· Fortvita Biologics (USA)Inc.· Source

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source

  Contact: Clinical Study Coordinator

• Recruiting

  A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  NCT06859424· Phase 2· Center for International Blood and Marrow Transplant Research· Source

  Contact: Leigh Anne Blackmon, MSW

• Recruiting

  Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

  NCT06726148· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Sam Stefanik

• Recruiting

  A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

  NCT06615050· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  SpaceIT Hydrogel System for Perirectal Spacing

  NCT06451614· Boston Scientific Corporation· Source

• Recruiting

  Study of REM-422 in Patients With AML or Higher Risk MDS

  NCT06297941· Phase 1· Remix Therapeutics· Source

  Contact: Eytan M Stein, MD (principal investigator)

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Summit Therapeutics· Source

• Active, not recruiting

  Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

  NCT05838768· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

  NCT05608044· Phase 2· Agenus Inc.· Source

• Recruiting

  Asciminib Roll-over Study

  NCT04877522· Phase 4· Novartis Pharmaceuticals· Source

  Contact: Shakira Pascual

• Active, not recruiting

  Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer

  NCT05183932· Washington University School of Medicine· Source

• Active, not recruiting

  A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

  NCT04978727· Phase 1· Children's Oncology Group· Source

• Active, not recruiting

  A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

  NCT05250973· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Lurbinectedin + Doxorubicin In Leiomyosarcoma

  NCT05099666· Phase 1/2· Massachusetts General Hospital· Source

• Recruiting

  First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  NCT05216432· Phase 1· Relay Therapeutics, Inc.· Source

  Contact: Relay Therapeutics Inc

• Recruiting

  Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

  NCT04819841· Phase 1/2· Kamau Therapeutics· Source

  Contact: Maria Paes Pena

• Recruiting

  Mechanisms of Resistance to PSMA Radioligand Therapy

  NCT05435495· University of California, San Francisco· Source

  Contact: Lisa Bodei, MD (principal investigator)

• Active, not recruiting

  A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

  NCT04835805· Phase 1· Genentech, Inc.· Source

• Active, not recruiting

  Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

  NCT04675333· Phase 2· ALX Oncology Inc.· Source

• Active, not recruiting

  Olaparib With Ceralasertib in Recurrent Osteosarcoma

  NCT04417062· Phase 2· Dana-Farber Cancer Institute· Source

• Active, not recruiting

  Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

  NCT04417621· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  NCT04585750· Phase 1/2· PMV Pharmaceuticals, Inc· Source

  Contact: Alison Schram, MD

• Active, not recruiting

  The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

  NCT04207944· Phase 2· Duke University· Source

• Recruiting

  Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  NCT04429542· Phase 1· Bicara Therapeutics· Source

  Contact: Eric Sherman, MD (principal investigator)

• Active, not recruiting

  A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

  NCT04396821· Phase 1/2· Transcenta Therapeutics (Hangzhou) Co., Ltd.· Source

• Active, not recruiting

  A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

  NCT03611868· Phase 1/2· Ascentage Pharma Group Inc.· Source

• Active, not recruiting

  Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

  NCT02259621· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Active, not recruiting

  Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer

  NCT02043158· M.D. Anderson Cancer Center· Source

• Active, not recruiting

  Improving Outcomes Assessment in Chronic GVHD

  NCT00637689· Fred Hutchinson Cancer Center· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Head and neck cancer3 recruiting
• Lung cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Childhood cancers2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Myelodysplastic syndromes2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Ovarian cancer2 recruiting
• Prostate cancer2 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple myeloma1 recruiting
• Pancreatic cancer1 recruiting
• Sickle cell disease1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Withdrawn

  HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

  NCT04482933· Phase 2· Pediatric Brain Tumor Consortium· Source

• Completed

  Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

  NCT05130268· Phase 4· American Heart Association· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· PrECOG, LLC.· Source

• Terminated

  A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

  NCT04150029· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

  NCT03604783· Phase 1· Sumitomo Pharma America, Inc.· Source

• Completed

  CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

  NCT03425279· Phase 1/2· BioAtla, Inc.· Source

• Completed

  Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

  NCT03275103· Phase 1· Genentech, Inc.· Source

• Completed

  Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

  NCT03238248· Phase 2· Vanderbilt-Ingram Cancer Center· Source

• Completed

  Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

  NCT02621151· Phase 2· NYU Langone Health· Source

• Completed

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Phase 2· Novartis Pharmaceuticals· Source